Investor Relations

Announcements and Notices

Performance Report

Investor Relations

Four pharmaceutical companies in the Liuyang Economic Development Zone have eight drugs proposed for inclusion in the 11th round of national centralized procurement.

Changsha Evening News, Changsha on the Go, October 31 (All‑media reporter Zhu Zehuan, correspondent Hu Jixing) — Recently, the results of the 11th round of national centralized bulk procurement of drugs were announced, with 55 medications selected. These cover commonly used medicines in areas such as anti‑infection, anti‑allergy, anti‑tumor, blood‑sugar‑lowering, blood‑pressure‑lowering, lipid‑lowering, and anti‑inflammatory/analgesic treatments. A total of 453 products from 272 enterprises nationwide have been granted preliminary eligibility for selection. In the Liuyang Economic Development Zone, four pharmaceutical companies have a combined eight drug products slated to be included in the 11th round of national centralized procurement.

2025

10-31

Three Products of Hunan Xianshi Pharmaceutical Selected in China’s 11th National Volume-Based Drug Procurement

CHANGSHA, Oct 28, 2025 — The preliminary winning list of the 11th round of China’s National Volume-Based Drug Procurement was released on October 27. Three core pharmaceutical products developed by Hunan Xianshi Pharmaceutical Co., Ltd., namely Procaterol Hydrochloride Inhalation Solution, Avatrombopag Maleate Tablets and Roxadustat Capsules, have been shortlisted in the program. The achievement recognizes the company’s product quality and R&D strength, and marks key progress in improving affordable medicine accessibility for domestic patients.

2025

10-28

[Exhibition Recap] Hunan Xianshi Pharmaceutical Concludes Successful Participation at CPHI China 2025

SHANGHAI, June 30, 2025 — CPHI China 2025, the three-day World Pharmaceutical Ingredients Exhibition, wrapped up at Shanghai New International Expo Center from June 24 to 26. As a reliable supplier specializing in APIs, pharmaceutical intermediates and excipients, Hunan Xianshi Pharmaceutical Co., Ltd. presented its core products and newly developed innovations at Booth E12D76, Hall E1. The company attracted wide attention and conducted in-depth communications with global clients and industrial counterparts.

2025

06-30

Hunan TV Reports on Xianshi Pharmaceutical’s Intelligent Oseltamivir Phosphate Granule Production Line

CHANGSHA, Feb 14, 2025 — Hunan Xianshi Pharmaceutical Co., Ltd. is accelerating digital transformation and smart manufacturing development amid national low-carbon and new-industry policy initiatives. On February 13, Hunan TV covered the company’s intelligent production line for oseltamivir phosphate granules during a live news report.

2025

02-14

Hunan Xianshi Pharmaceutical Co., Ltd. has donated an emergency rescue vehicle to the Yueyang Blue Sky Rescue Team, supporting the cause of public emergency response!

Hunan Xianshi Pharmaceutical Co., Ltd. has donated an emergency rescue vehicle to Yueyang Blue Sky Rescue Team to support local public emergency rescue initiatives.

2024

11-13

Xue Haipeng, Deputy General Manager of Hunan Xianshi Pharmaceutical Co., Ltd., and his delegation paid a visit to the university for a research tour.

On October 17–18, a delegation led by Xue Haipeng, Deputy General Manager of Hunan Xianshi Pharmaceutical Co., Ltd., and Luo Ming, Director of R&D, paid a visit to our institute for a fact-finding mission. The institute’s President Ai Weiping, together with Vice Presidents Hou Jihua and Qiao Xinjiang, received the delegation and held a symposium.

2024

10-22

< 123 >